- Home
- AZ vs VOR Comparison
AZ vs VOR Comparison
Compare AZ & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZ | VOR |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.5M | 207.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AZ | VOR |
|---|---|---|
| Price | $6.48 | $14.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $20.00 | ★ $66.63 |
| AVG Volume (30 Days) | 475.6K | ★ 3.5M |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,463,000.00 | N/A |
| Revenue This Year | $1,343,857.60 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 41.45 | N/A |
| 52 Week Low | $5.00 | $2.62 |
| 52 Week High | $12.36 | $65.80 |
Technical Indicators
Market Signals| Indicator | AZ | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 56.19 | 54.07 |
| Support Level | $5.64 | $12.05 |
| Resistance Level | $6.59 | $15.27 |
| Average True Range (ATR) | 0.47 | 1.96 |
| MACD | 0.09 | 0.65 |
| Stochastic Oscillator | 75.00 | 64.21 |
Price Performance
Historical ComparisonAbout AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.